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Cerebrospinal fluid markers 
for synaptic function and Alzheimer 
type changes in late life depression
Nikias Siafarikas1*, Bjørn‑Eivind Kirsebom2,3, Deepak P. Srivastava13, Cecilia M. Eriksson1, 
Eirik Auning1, Erik Hessen4,5, Geir Selbaek6,7,8, Kaj Blennow9,10, Dag Aarsland11 & 
Tormod Fladby4,12
To explore markers for synaptic function and Alzheimer disease (AD) pathology in late life depression 
(LLD), predementia AD and normal controls (NC). A cross‑sectional study to compare cerebrospinal 
fluid (CSF) levels of neurogranin (Ng), Beta‑site amyloid‑precursor‑protein cleaving enzyme1 (BACE1), 
Ng/BACE1 ratio and Amyloid‑β 42/40 ratio, phosphorylated‑tau and total‑tau in LLD with (LLD AD) 
or without (LLD NoAD) AD pathology, predementia AD and normal controls (NC). We included 145 
participants (NC = 41; predementia AD = 66 and LLD = 38). LLD comprised LLD AD (n = 16), LLD NoAD 
(n = 19), LLD with non‑AD typical changes (n = 3, excluded). LLD AD  (pADJ < 0.05) and predementia 
AD  (pADJ < 0.0001) showed significantly higher Ng than NC. BACE1 and Ng/BACE1 ratio were altered 
similarly. Compared to LLD NoAD, LLD AD showed significantly higher Ng  (pADJ < 0.001), BACE1 
 (pADJ < 0.05) and Ng/BACE1 ratio  (pADJ < 0.01). All groups had significantly lower Aβ 42/40 ratio than NC 
(predementia AD and LLD AD, p < 0.0001; LLD NoAD, p < 0.05). Both LLD groups performed similarly 
on tests of memory and executive function, but significantly poorer than NC. Synaptic function in LLD 
depended on AD pathology. LLD showed an association to Amyloid dysmetabolism. The LLD groups 
performed poorer cognitively than NC. LLD AD may be conceptualized as “predementia AD with 
depression”.
Late life depression (LLD) is a burden for patients, relatives and healthcare-systems1 with high treatment 
 resistance2 and poorly understood mechanisms. Clinically, LLD is often hard to separate from Alzheimer’s disease 
in early, predementia stages (predementia AD) which is defined as biomarker evidence of AD pathology with 
cognitive impairment but no  dementia3. An association of LLD to AD pathology such as amyloid plaques has 
been  hypothesized4 but results are  inconsistent5 and a recent study performing Amyloid-β (Aβ) positron emis-
sion tomography (PET)6 in patients with LLD failed to provide evidence for an association between Aβ and LLD. 
Synaptic loss and dysfunction are an early feature of AD and tightly connected to amyloid plaque  formation7,8: 
the presynaptic Beta-site amyloid-precursor-protein (AβPP) cleaving enzyme 1 (BACE1) instigates the formation 
of Amyloid-β (Aβ) species. Innate immune activation is involved in BACE1 activation and synaptic loss is likely 
linked to the release of the postsynaptic protein neurogranin (Ng)9–11. Ng is mainly expressed in dendritic spines 
in the neocortex and the  hippocampus12 and is associated to cognitive function and memory  potentiation13,14. 
Elevated CSF levels of Ng and BACE1 are regarded specific for  AD13,15 already in predementia stages. Although 
predementia AD and LLD show a considerable clinical overlap, it is unclear if LLD shows overlapping AD 
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specific constellations of Ng and BACE1. Constellations of Ng and BACE1 in LLD similar to those in AD could 
indicate common biological underpinnings of the two conditions and might in part explain cognitive symptoms 
in LLD. Lower levels of Ng and BACE1 in LLD than in AD have been reported in two  studies16,17. Only one of 
those  studies16, though, included normal controls (NC) and found no significant difference in CSF Ng levels 
between NC and LLD, while both NC and LLD had lower Ng levels than AD. However, neither study defined 
normal or pathological AD status in their LLD groups. To better study synaptic function and AD pathology in 
LLD, an approach is needed where LLD patients are stratified according to presence or absence of AD pathology. 
This would provide the opportunity to study markers for synaptic function in LLD unbiased from possible AD 
pathology. To the best of our knowledge, no such study has been performed.
To study the relationship between LLD, synaptic function, AD pathology and cognitive performance we 
included patients with LLD, predementia AD and NC. We expected to find some LLD patients with normal AD 
biomarkers similar to NC and others with signs of AD pathology as in predementia AD. Our main hypothesis 
was that synaptic function measured with Ng, BACE1 and Ng/BACE1 ratio levels in LLD depends onthe status 
of AD biomarkers in LLD: LLD with normal AD biomarkers (LLD NoAD) would show Ng, BACE1 and Ng/
BACE1 ratio levels similar to NC; LLD with signs of AD pathology (LLD AD) would show higher Ng, BACE1 
and Ng/BACE1 levels than NC as is typical for AD. Moreover, we wanted to compare cognitive performance 
between the included groups and expected LLD patients to perform poorer than NC.
Material and methods
Cohorts and recruitment. The study was based on the Norwegian multicentre project “Dementia Disease 
Initiation (DDI)”18, including participants from a neurocognitive (“DDI cog”) and a neuropsychiatric (“DDI 
plus”) sub cohort. The study has been approved by the ethics committee “Regional Committees for Medical 
and Health Research Ethics (REK)”. All participants gave their informed consent in writing. All methods were 
performed in accordance with relevant REK guidelines and regulations and in accordance with the Declaration 
of Helsinki.
The “DDI cog” recruited participants from memory clinics and through media. Inclusion criteria for patients 
in DDI cog were subjective cognitive decline (SCD) and mild cognitive impairment (MCI). The “DDI plus” 
recruited patients from the Department for old age psychiatry, Akershus University-Hospital; inclusion criteria 
in DDI plus were psychiatric diagnoses based on ICD-10. Cognitively healthy NC were included from spouses of 
patients and from orthopaedic patients who underwent surgery in spinal anaesthesia, with CSF collected before 
the injection of the anaesthetic. For neuropsychological assessment of NC and patients see below.
Exclusion criteria in both cohorts were dementia or severe physical illness. In the DDI cog cohort psychi-
atric illness such as a diagnosis of depression, bipolar disorder or schizophrenia, which may impair cognition 
were exclusion criteria. Participants from both cohorts underwent medical examination, neuropsychological 
assessment (see below), collection of plasma and CSF samples according to study protocol within 3 months 
from  inclusion18.
Diagnosis of LLD. Diagnoses in DDI plus were made according to ICD-1019. In addition to clinical exami-
nation by a consultant psychiatrist or psychologist, structured diagnostic procedure included the Mini-Inter-
national Neuropsychiatric Interview (M.I.N.I.)20, the neuropsychiatric inventory questionnaire (NPI-Q)21 and 
the Geriatric depression scale (GDS)22. The clinical diagnoses were discussed in multidisciplinary consensus 
meetings including consultant psychiatrists, psychologists and neuropsychologists. In this study we included 
patients with a diagnosis of depression according to ICD-10 (F32)23. There is no defined age cut-off for LLD, but 
patients in the department for old-age psychiatry are usually 65 years or older. To describe depression in this 
patient group as LLD was in line with common practice in most studies into LLD where patients with LLD are 60 
to 65 and  older24. In addition, we reported information on the prevalence of Late-onset depression (LOD) (first 
occurrence after 60 years of  age25) and comorbid anxiety (in accordance with ICD-10  F4123) in the LLD groups.
Neuropsychological assessment. Neuropsychological assessment in addition to clinical examination 
was done to stage participants as NC, SCD or MCI based on demographically adjusted T-scores from neuropsy-
chological tests (see below) according to published  criteria26,26. We applied the “Mini Mental State Examination 
(MMSE-NR)”28 and the clock-drawing-test29 for cognitive screening; tests on verbal learning and memory recall 
(Consortium to Establish a Registry for Alzheimer’s Disease [CERAD] word list test)30; psychomotor speed and 
divided attention (trail-making test A and B [TMT A and B])31; verbal fluency (Controlled Oral Word Asso-
ciation Test [COWAT])32; visual object and space perception (VOSP)33. Demographically adjusted T-scores of 
CERAD word list (recall)34,  VOSP33, TMT B and COWAT 35 were used for cognitive staging, defined as impaired 
if lower than 1.5 standard deviation below the normal population. Details on the neuropsychological battery 
have been provided  elsewhere36.
CSF analysis and AD pathology. Lumbar puncture procedures and CSF handling were performed as 
described  in18. The QuickPlex SQ 120 system from MesoScale Discovery (MSD, MD, USA) was used to measure 
Aβ42 and Aβ40 in a multiplex setup using V-plex Ab Peptide Panel 1 (6E10) kit (K15200E-1). T-tau and P-tau 
concentrations were measured with Innotest kits (Fujirebio, Ghent, Belgium); Ng and BACE1 with Euroimmun 
AG kits (Luebeck, Germany)37.
AD pathology was assessed according to normal or pathological Amyloid (A), Phosphorylated (P)-tau (T) 
and total (T)-tau (N) (introduced as A/T/N index  in38). To define pathological Aβ levels (A) we used the Aβ42/40 
ratio, which has been suggested superior to Aβ42 alone to distinguish  AD39. An optimum cut-off for Aβ42/40 
ratio at ≤ 0.077 was determined following using receiver operating curve (ROC) analysis using visual read of 
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[18F]-Flutemetamol PET scans as the standard of truth. We used cut-offs modified from Sjogren,  Vanderstichele40 
for P-tau (≥ 80 pg/ml) and T-tau (> 300 pg/ml < 50 years; > 450 pg/ml 50–69 years; > 500 pg/ml for ≥ 70 years).
Study design. A total of 145 participants were included for the present study, whereof 107 patients and con-
trols were included from the DDI cog cohort, and 38 cases with LLD from the DDI plus cohort. Stratification by 
A/T/N yielded the following groups: NC group with normal cognition and normal AD biomarkers (n = 41, A-/T-
/N-); a “Predementia AD” group comprising SCD and MCI patients with pathologic AD biomarkers (n = 66, A+/
T+/N+); we stratified LLD patients into those with normal AD biomarkers (LLD NoAD; n = 19, A−/T−/N−,) 
those on the AD continuum (LLD AD; n = 16, A+/T*/N* where “*” indicates a positive or negative parameter) 
for our main analyses. We excluded LLD patients with non-AD pathologic changes (n = 3, A−/T*/N*) from fur-
ther analyses, because the focus of this study was to explore possible effects of AD pathology on synaptic func-
tion and because of the group size. A flowchart (Fig. 1) and a table with detailed A/T/N characteristics for the 
LLD groups are provided (Table 1). The prevalence of LOD and anxiety in the LLD groups is provided (Table 2).
Figure 1.  Inclusion of participants and groups.
Table 1.  Combinations of CSF AD parameters in the LLD group. A+ = pathologic Amyloid beta42/40; 
T+ = pathologic phosphorylated Tau; N+ = pathologic marker of neurodegeneration (here total Tau).
Normal AD biomarkers “LLD NoAD” Alzheimer’s continuum “LLD AD” Non-AD pathologic change
A−/T−/N− A+/T−/N− A+/T−/N+ A+/T+/N+ A−/T+/N− A−/T−/N+ A−/T+/N+
19 (50%) 7 (18.4%) 2 (5.3%) 7 (18.4%) 1 (2.6%) 1 (2.6%) 1 (2.6%)
Table 2.  Prevalence of Late-onset depression and comorbid anxiety in the LLD groups. Late-onset was defined 
when LLD occurred after the age of 60. Anxiety was defined in accordance to ICD10 (F41). Chi square for 1) 
1.9 (p = 0.40), for 2) 2.1 (p = 0.35).
LLD NoAD (n = 19) LLD AD (n = 16) Non-AD pathologic change (n = 3)
Late-onset (%within group)1) 52.6 (n = 10) 75.0 (n = 12) 66.7 (n = 2)
Comorbid anxiety (%within group)2) 36.8 (n = 7) 43.8 (n = 7) 0.0 (n = 0)
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Statistics. Statistical analyses were performed with SPSS v 26 and R version 3.6.3. For between-group com-
parisons of demographics and clinical characteristics, one-way ANOVA was used for variables with assumed 
normal distributions (age, years of education and demographically adjusted T-scores from CERAD memory 
recall, TMT-B, COWAT and VOSP silhouettes) and the Kruskal–Wallis test was used for variables with non-
normal distributions (MMSE and GDS). Differences in sex distributions were assessed with a chi-square test. 
For CSF measures, we fitted ANCOVA models with age and sex as covariates. In total, 6 ANCOVAS were carried 
out since we assessed 6 CSF markers (Aβ42/40, P-tau, T-tau, Ng, BACE1, Ng/BACE1). In preliminary models, 
treatment with antidepressants was included as a covariate but was omitted for reasons of parsimony since it had 
no significant effect. All except the Ng/BACE1 ratio and Aβ42/40 ratio showed distributions with kurtosis and/
or skewness that led to violations of assumptions of ANCOVA analyses and were thus log-transformed prior 
to final analyses. If Kruskal–Wallis tests, ANOVA or ANCOVA models showed significant group differences 
(p < 0.05), planned comparisons between groups in accordance with our hypotheses were carried out: (1) symp-
tom groups were compared to the NC group, (2) the LLD noAD group was compared to the LLD AD group. 
However, to reduce the family wise error rate associated with multiple testing of the same synapse markers indi-
vidually (Ng and BACE1), and as a ratio (Ng/BACE1) the Holm-Bonferroni sequential procedure was used for 
these planned comparisons (twelve comparisons in total). The adjusted p-values  (pADJ) are in accordance with 
significance thresholds following this procedure.
Results
The LLD patients emerged as a heterogenous group with respect to AD biomarkers based on A/T/N index: LLD 
NoAD (n = 19), LLD AD (n = 16) and LLD with non-AD typical changes (n = 3 which we did not include in 
further analyses due to our hypotheses and research questions) (Table 1). Details pertaining to between group 
comparisons of demographics, clinical and CSF markers are shown in Table 3. NC were significantly younger 
than all other groups (NC vs predementia AD p < 0.01; NC vs LLD NoAD p < 0.0001; NC vs LLD AD p < 0.001) 
and had significantly more education years than LLD NoAD (p < 0.0001). The LLD groups and predementia AD 
showed significantly higher GDS scores than NC (p < 0.0001). Both LLD groups showed significantly poorer 
performance than NC in memory (CERAD recall T-score; LLD NoAD p < 0.0001; LLD AD p < 0.001) and execu-
tive function (TMT-B: LLD NoAD p < 0.001; LLD AD p < 0.001); in addition, the LLD AD group showed poorer 
visuospatial performance than NC (VOSP p < 0.01). None of these parameters showed significant differences 
between the LLD groups. Late-onset LLD was differently prevalent (p = 0.40) in the LLD groups (LLD AD 75.0%; 
non-AD pathological changes 66.7%; LLD NoAD 52.6%). Anxiety as a comorbidity was more prevalent (p = 0.35) 
in the LLD AD group (43.8%) than in the LLD NoAD (36.8%) and non-AD pathological changes (0%) groups.
CSF Ng and BACE1. Details pertaining to between-group analyses are shown in Table 3. LLD AD and 
predementia AD showed significantly higher Ng levels than NC (LLD AD,  pADJ < 0.05; predementia AD, 
 pADJ < 0.0001); LLD NoAD showed Ng levels similar to NC. BACE1 levels were altered in a parallel fashion: LLD 
AD and predementia AD showed higher BACE1 levels than NC (LLD AD, n.s.; predementia AD,  pADJ < 0.01); 
LLD NoAD showed BACE1 levels similar to NC. The Ng/BACE1 ratio followed the same pattern (LLD AD vs 
NC  pADJ < 0.05; predementia AD vs NC  pADJ < 0.0001; LLD NoAD vs NC n.s.) (Fig. 2).
Notably, the depression groups LLD AD and LLD NoAD showed significant differences in Ng, BACE1 and Ng/
BACE1 ratio with higher levels for Ng  (pADJ < 0.001), BACE1  (pADJ < 0.05) and the Ng/BACE1 ratio  (pADJ < 0.01) 
in the LLD AD group.
CSF Aβ42/40 ratio, P‑tau and T‑Tau. Details pertaining to between-group analyses are shown in Table 3. 
All patient groups had significantly lower Aβ42/40 ratio than NC (predementia AD and LLD AD, p < 0.0001; 
LLD NoAD, p < 0.05). P-tau and T-tau were significantly higher in predementia AD and LLD AD than in NC 
(p < 0.0001), but similar in NC and LLD NoAD. The two LLD groups exhibited significant differences in all three 
parameters: the LLD AD group showed significantly lower (p < 0.0001) Aβ42/40 ratio and significantly higher 
(p < 0.0001) P-tau and T-tau levels than LLD NoAD.
Discussion
The mechanisms of LLD are unclear. While LLD shares clinical features with predementia AD, it is unclear to 
which extent this reflects shared biological features. Here we could show that according to A/T/N index, some 
LLD patients (LLD AD) exhibited pathological AD markers thus sharing CSF findings with predementia AD 
patients and being on the AD  biocontinuum41, while other LLD patients (LLD NoAD) showed normal AD bio-
markers closer to NC. Interestingly, although in normal ranges, the CSF Aβ42/40 ratio was significantly lower 
in LLD NoAD than in NC. We could support our main hypothesis that CSF Ng and BACE1 levels would depend 
on AD status in LLD. LLD AD patients had significantly higher Ng and BACE1 levels than LLD NoAD patients 
and exhibited changes of these synaptic proteins parallel to those in predementia AD patients, albeit to a lesser 
extent. LLD NoAD patients, on the other hand, exhibited levels of Ng, BACE1 and Ng/BACE1 ratio similar to 
NC. The neuropsychological performance of both LLD groups was significantly poorer than that of NC, with 
poorer memory function (CERAD recall), poorer executive function (TMT-B) in both LLD groups and, in the 
LLD AD group, also poorer visuospatial performance (VOSP). A smaller portion of the LLD patients showed 
non-AD pathologic changes, exhibiting normal Aβ42/40 levels, but pathological P-tau and N for neurodegen-
eration or a combination of both (A-/T*/N*). In these patients, other mechanisms such as tauopathies or other 
neurodegenerative diseases may be associated to LLD. LLD may appear as a recurrent disease after debut in earlier 
life (EOD) or for the first time in later life (LOD)25. Biological differences between EOD and LOD have been 
 discussed25,42, which is in line with our findings of a higher prevalence of LOD in the LLD AD group. We could 
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further show that a larger portion in the LLD AD group than in the LLD NoAD group had comorbid anxiety, 
which concurs with the assumption that anxiety may be a prodrome or a risk-factor of  AD43,44.
The association between Aβ pathology and LLD is unclear and results are  conflicting42. In our sample, all LLD 
patients had significantly lower CSF Aβ42/40 ratios than NC, although the LLD NoAD group was within normal 
ranges. Since we could show that BACE1 levels were normal in LLD NoAD, other mechanisms than BACE1 
activity likely account for the lowered Aβ42/40 ratio in LLD NoAD, putatively linked to depressive  symptoms45. 
It has been  speculated46 that lower Aβ in LLD follows a decreased neuronal  activity47 rather than amyloid plaque 
formation as is the case in AD. Lower, but still normal CSF concentrations of Aβ42/40 in the LLD NoAD group 
may suggest incipient AD linked mechanisms or other factors leading to lower CSF Aβ42/40 in LLD NoAD. 
Overproduction of Aβ has been  hypothesized48 to be a repair mechanism for neuronal dysfunction in the context 
of AD and depression. The lack of significant differences in P-tau and T-tau concentrations between LLD AD 
Table 3.  Between-group comparisons of CSF biomarkers, demographics, clinical including 
neuropsychological data. n = sample size; n.s. = non-significant results; *no comparisons performed; 
F = F-statistic; χ2 = chi-square H = Kruskal–Wallis test; η2 = eta-squared; ηp2 = partial eta squared; P = p-value; 













n = 16 1 versus 2 1 versus 3 1 versus 4 3 versus 4
Age
Mean (SD) 64 (4.8) 67.9 (8.0) 71.9 (6.9) 72.9 (6.8) F(3,136) = 8.7 η
2 = 0.16 
(< 0.0001) < 0.01 < 0.0001 < 0.001 n.s
Male
n (%) 18 (43.9) 38 (57.6) 8 (42.1) 6 (37.5) χ2 = 3.6 (n.s) * * * *
Education years
Mean (SD) 14.4 (3.2) 13.2 (3.2) 11.3 (2.4) 12.7 (3.2) F(3,136) = 4.7 η
2 = 0.09 
(< 0.01) n.s < 0.0001 n.s n.s
GDS
Median (IQR) 0 (1) 2.0 (3) 5.0 (6) 5.0 (4) H(3) = 47.9, η
2 = 0.33 
(< 0.0001) < 0.0001 < 0.0001 < 0.0001 n.s
MMSE
Median (IQR) 29 (2) 27 (4) 29 (5) 29 (5) H(3) = 22.6 η
2 = 0.14 
(< 0.0001) < 0.0001 n.s n.s n.s
CERAD Recall T
Mean (SD) 54.6 (8.0) 35.0 (13.1) 40.9 (11.5)(n=18) 42.9 (8.9) F(3,137) = 26.1 η
2 = 0.36 
(< 0.0001) < 0.0001 < 0.0001 < 0.001 n.s
TMT-B T
Mean (SD) 48.6 (9.1)(n=40) 37.6 (14.1) 35.0 (18.1)(n=16) 34.6 (15.4)(n=14) F(3,132) = 7.4 η
2 = 0.15 
(< 0.0001) < 0.0001 < 0.001 < 0.001 n.s
COWAT T
Mean (SD) 52.8 (9.5)(n=40) 48.9 (10.1) 44.9 (11.5)(n=16) 48.3 (7.3)(n=15) F(3,133) = 2.8 (n.s) * * * *
VOSP T
Mean (SD) 54.0 (10.2)(n=40) 48.2 (10.4)(n=62) 49.5 (9.4)(n=18) 45.7 (11.3)(n=15) F(3,131) = 3.4 η
2 = 0.07 
(< 0.05) < 0.01 n.s < 0.01 n.s
CSF Aβ42/40 ratio
Mean (SD) 0.101 (0.101) 0.047 (0.008) 0.096 (0.010) 0.051 (0.014) F(3,136) = 325.4 ηp
2 = 0.88, 
(< 0.0001) < 0.0001 < 0.05 < 0.0001 < 0.0001
CSF P-tau
Mean (SD) 50.6 (13.1) 118.2 (34.5) 51.9 (11.7) 80.4 (32.2) F(3,136) = 90.6, ηp
2 = 0.67, 
(< 0.0001) < 0.0001 n.s < 0.0001 < 0.0001
CSF T-tau
Mean (SD) 289.0 (88.0) 858.3 (248.9) 300.5 (76.3) 576.9 (271.4) F(3,136) = 121.2 ηp
2 = 0.73 
(< 0.0001) < 0.0001 n.s < 0.0001 < 0.0001
CSF Ng
Mean (SD) 303.8 (107.1) 559.8 (195.5) 264.4 (83.9) 508.9 (356.1) F(3,136) = 35.2 ηp
2 = 0.44 
(< 0.0001) < 0.0001
a n.sa < 0.05a < 0.001a
CSF BACE1
Mean (SD) 2205.7 (585.9) 2847.4 (770.2) 2211.2 (600.5) 2849.8 (1000.3) F(3,136) = 8.9 ηp
2 = 0.16 
(< 0.0001) < 0.01
a n.sa n.sa < 0.05a
CSF Ng/BACE1
Mean (SD) 0.137 (0.03) 0.197 (0.04) 0.123 (0.03) 0.167 (0.05) F(3,136) = 34.4 ηp
2 = 0.43 
(< 0.0001) < 0.0001
a n.sa < 0.05a < 0.01a
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NoAD and NC indicates that tau-pathology or neurodegeneration are not features of LLD NoAD. Our results 
for levels of Ng and BACE1 in LLD are partly in line with other  results16,16 of lower Ng levels in LLD than in AD. 
Neither of these studies, however, stratified LLD for possible AD pathology. Therefore, concluding from our 
finding of a LLD NoAD group, a possible explanation for their  findings16,16 of lower Ng and BACE in LLD than 
in AD may be that a subset of their patients had normal AD biomarkers shifting the levels of Ng and BACE to 
statistically lower levels than in AD. While our findings of Ng and BACE in the LLD NoAD group provide no 
evidence for synaptic dysfunction in LLD, there is other evidence of synaptic dysfunction in LLD. For example, 
LLD may be associated with reduced synaptic  density49. Chronic stress, as in LLD, may lead to reduced spine 
density in the limbic  system50, a central region for emotional regulation. Possibly, synaptic dysfunction in the 
hippocampus contributes to both affective and cognitive symptoms in  depression49, which would be compatible 
with poorer memory in our LLD groups.
Showing lower cognitive performance and signs of AD pathology without dementia, the LLD AD group can 
be conceptualized as “Predementia AD with depression”. It has been  suggested51 to describe an “AD positive” 
subtype of LLD. However, we would suggest the other way around to describe a subtype “Predementia AD with 
depression” since it cannot be excluded that the AD pathology contributes to depression in this group in the sense 
of “neuro”-psychiatric symptoms. This concurs with recent work demonstrating that mild psychiatric symptoms 
may represent prodromal AD (“mild behavioural impairment”)43 and with the  assumption52 that psychiatric 
phenotypes can be indistinguishable clinically while they differ etiologically. Our finding of lower Aβ levels in 
LLD AD and poorer visuospatial performance is in line with previous  findings42. Poorer visuospatial performance 
may be associated to pathology in the parietal lobe in early  AD53. A relatively new biomarker strongly associated 
to cognitive performance in AD but also to differentiate AD from other underlying pathologies is the Ng/BACE 
 ratio54. It has been shown that higher values of the Ng/BACE are associated with poorer memory performance in 
predementia AD  patients55. This is in line with a significantly higher Ng/BACE ratio and poorer memory perfor-
mance in our LLD AD group. The LLD NoAD group also performed poorer in memory function and executive 
function (TMT-B) than NC, but showed no significant difference to NC in visuospatial abilities, which may be 
associated to normal AD biomarker status in the LLD NoAD group. Probably, in LLD NoAD other mechanisms 
than those leading to alterations in Ng or BACE1 drive the cognitive symptoms. As amyloid precursor protein 
Figure 2.  Scatter dot plots for CSF concentrations of (A) Aβ42/40 ratio, (B) P-tau and (C) T-tau (CSF 
markers for AD pathology) and of (D) neurogranin (Ng), (E) BACE1 and (F) Ng/BACE1 ratio (CSF Synapse 
biomarkers). The lines in the plots represent the mean values, the bars the standard deviation. Statistical 
significance at p < 0.05; n.s. = non significant. NC = normal controls; predementia AD = predementia Alzheimer’s 
disease; LLD NoAD = late life depression without AD pathology; LLD AD = late life depression with AD 
pathology (pathologic Aβ42/40 ratio, varying combinations of pathologic P-tau and T-tau).
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function, and Aβ-metabolism is linked to synaptic plasticity and learning, the cognitive symptoms in the LLD 
NoAD group may be linked to Aβ metabolism reflected in the lower, albeit normal levels of Aβ 42/40 ratio. Poorer 
cognitive performance in LLD NoAD is generally in line with previous results and clinical criteria implying that 
cognitive symptoms are an integral part of  depression19,56.
Limitations of this study include the cross-sectional design, which is why possible causal or temporal associa-
tions of clinical and CSF markers cannot be ascertained. Of note, data are being collected and the longitudinal 
course will be described in subsequent papers. It is still unclear how plasma levels of Aβ, P-tau and T-tau cor-
relate with central-nervous levels of Aβ, P-tau and T-tau. A high correlation of plasma Aβ, P-tau and T-tau to 
respective PET findings has been  reported57. We will address the relation of AD markers in plasma and CSF in 
a subsequent study. We will augment the included CSF markers with alpha synuclein and other synaptic mark-
ers. Another limitation is the rather small sample size, which is also why we did not further categorize the LLD 
AD group (LLD AD A+/T+/N+ etc.). The GDS scores in our LLD groups were low, which may be explained by 
inclusion after discharge and that patients with more severe depression were often too frail to be included or to 
give informed consent. Our LLD groups were significantly older than the NC. We see this as a limitation in a 
study into age-related disorders and included age as a covariate.
A strength of the study lies in the biologically defined groups based on CSF AD pathology, enabling us to study 
synaptic markers in a LLD NoAD group which is unbiased from AD pathology. The value of our findings lies in 
the demonstration of distinct LLD groups where one showed no AD pathology and synaptic markers similar to 
NC, while the other showed a typical AD profile including characteristic changes of synaptic markers. Moreover, 
we assessed Aβ alterations both continuously and dichotomized. Although pseudodepression and pseudode-
mentia are being discussed  controversially56, our findings may be of value in the discussion of these concepts.
In conclusion, we could demonstrate that LLD is heterogenous with respect to AD pathology. We could sup-
port our main hypothesis and found higher Ng, BACE1 and Ng/BACE1 ratio in LLD AD than in LLD NoAD and 
NC. This finding suggests that Ng and BACE1 in LLD depend on AD status as has been reported typical for AD. 
Similar Ng and BACE levels in LLD NoAD and NC indicate that these markers do not directly reflect mechanisms 
underlying depression in the LLD NoAD group. Our findings suggest associations of Aβ metabolism to LLD. 
Both LLD groups showed significantly lower Aβ42/40 ratios than NC. The LLD AD group showed pathological 
Aβ42/40 levels and AD typical Ng and BACE1 alterations, which is why he LLD AD group may be conceptual-
ized as a “predementia AD with depression” group. The LLD NoAD group showed Aβ42/40 levels lower than 
in NC but in normal ranges which may suggest that mechanisms other than in AD are involved. Examination 
of CSF AD pathology in LLD patients should be considered on a routine basis since predementia AD may be 
associated. It has been reported that Aβ levels may predict poorer response to antidepressant  treatment51. Except 
in visuospatial performance, the LLD groups are clinically similar, while they differ in CSF findings. This may 
indicate that different mechanisms drive the clinical signs in our LLD groups. Our study may contribute to a 
better understanding of LLD underlying mechanisms and to a better conceptualization of LLD considering clini-
cal overlap with predementia AD. The clinical implications of our findings lie in the CSF based identification of 
LLD patients with a higher risk of developing AD dementia.
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